The refill email arrived on schedule, at the same dose as the month before. For three weeks, the scale has shown the number you wrote down the day you started. Your doctor read the panel from your annual visit and gave you the sentence you have heard before: “Your labs are fine.” You have reached goal weight on a GLP-1. Nobody has told you what comes next. You can hold the dose, lower it or stop. Regain is the outcome everyone warns you about and nobody has measured for you.
This piece follows one composite patient through her first three months with GoodLife Health. She is assembled from common situations and is not a real person. GoodLife Health is a clinician-led membership that manages the long haul on a GLP-1. It draws labs before a dose changes and every quarter after. A clinician who stays reads every result with the patient. The question here is the one you are asking. Do you need labs at all when your doctor says yours are fine?
- The panel called fine at an annual visit was drawn before anyone asked about your next dose.
- A normal result sits inside a population range and says little about where your own markers are heading.
- Hold, lower or stop is a clinical decision made with you on the evidence of your own panel.
- GoodLife Health draws nine biomarkers four times a year for $299 a month at any dose.
- Nobody can promise the weight stays off. A panel every 90 days shows how your markers respond to the plan.
- This week, ask your doctor's office for the actual numbers and the date they were drawn.
The month after goal weight
Call her Dana. She runs a sales team for a regional manufacturer and spends more of her week in airports than she would like. She started semaglutide through an online prescriber after the weight that arrived with years of desk work stopped answering to anything she tried. The intake was a questionnaire. No blood was drawn before the first prescription or at any point after it.
The medication worked for her. In STEP 1, semaglutide 2.4 mg produced roughly 15% average body-weight loss over 68 weeks. A trial like that measures how far people get. Dana's question begins where the headline number ends.
Her dose rose on the prescriber's schedule. The nausea of the early months settled and the weight came off. Then one morning, the scale showed her number. The prescriber's next message offered the same dose on automatic renewal.
Her primary care doctor saw her for the annual visit, ordered the usual panel and spent about eight minutes with her. When she asked whether her results meant she could come off the medication, the answer was kind and brief. Her labs were normal. She should do what felt right.
It was a kind answer to a question she had not asked. Dana had not wanted to know whether she was sick. She wanted to know which of three paths was hers. Should she stay on the dose that got her here, perhaps for years? Could she step down slowly and see what held? If she stopped, how fast would the weight return?
She read the forums at night. One person had stopped and held steady. The next had stopped and regained most of it within a season. Each was certain their own story was the rule. Dana packs her medication for every trip. She also carries a quiet worry that the work of the past months could come undone. What she wants is a clinician who reads her numbers and makes the decision with her.
What the word fine was measuring
An annual visit usually orders a basic panel. Each result is printed beside a reference range drawn from a large population. A number inside that range is marked normal. The label means Dana did not stand out from many other people on one morning. It cannot tell her where her own numbers were before the weight came off. It cannot tell her where they are heading as the dose changes.
Our definitive guide to cardiometabolic optimization describes the Biomarker Audit differently. Its markers are drawn every 90 days and read against optimal ranges in place of population reference ranges. The difference matters most at a moment like Dana's, when a decision is about to change the conditions the last panel measured.
There is a second gap. Dana's panel was drawn on one morning on the dose she was taking that morning. The decision in front of her concerns the dose she takes next, which may be lower or may be none. No single panel, however clean, can describe a change that has not happened yet.
The panel her doctor called fine was drawn on the dose that got her here and cannot speak for the dose that keeps her here.
The markers on that panel matter as much as the date. Medicine is moving toward testing before treating. Clinicians who want to see cardiometabolic risk early now draw ApoB where LDL once stood alone and fasting insulin where glucose once stood alone. Fasting insulin can show strain before glucose turns abnormal. The CDC counts more than 130 million American adults living with diabetes or prediabetes. NHANES data put the share of U.S. adults who are metabolically healthy at only 12%. Against figures like those, a normal glucose on one morning settles very little.
The guide also states the rule we follow on dosing. Doses are held at the lowest effective level. When the labs support it, deprescribing counts as a success. That rule only works if someone draws the labs. Without them, a dose comes down on a feeling and goes back up on a fear.
Hormone and metabolic markers can change without symptoms. A plan to hold, lower or stop a GLP-1 is checked on the next panel, about 90 days later.
We do not know whether Dana will regain. Nobody does, whatever the forums say. No panel predicts it. What a panel can do is show, every 90 days, how her markers respond to the plan she and her clinician choose. That is a smaller promise than the ones she has read online. It is also one we can keep.
The question went unanswered for a reason built into how her care was paid for. A prescriber paid by the refill has little reason to raise a lower dose or a stop. A doctor with eight minutes has no time to work the question up. Neither is acting in bad faith. The structure around them never asks the question.
Dana's first three months with GoodLife Health
GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app. It is precision direct primary care for cardiometabolic optimization. For a patient at goal weight on a GLP-1, that means a clinician who manages the long haul, with labs before the dose changes and every quarter after. Over three months, it would look like this for Dana.
Dana's first three months
| Stage | What is checked | Why it matters |
|---|---|---|
| Before the first visit | Eligibility, intake and the first panel | The first visit opens with her numbers |
| Month 1 | Nine biomarkers read with the clinician | Sets the baseline for any dose decision |
| Month 2 | Messages with the care team between visits | Her questions get answers in writing |
| Month 3 | The same markers drawn again | Shows how her markers responded to the plan |
Before the first visit
Dana starts with the eligibility check. The intake follows, then the checkout. At checkout, $598 is held on her card to cover the first two months. It is a hold. It is charged only once a clinician accepts her into care. If the clinician cannot accept her, the hold is released and she is never charged. Once she is accepted, the first two months are charged and are non-refundable. Not everyone is accepted. A clinician's review of her intake decides it.
Her first panel is drawn before she ever speaks with the clinician, so the first visit opens with her numbers. Every result lands in her own hands as well as the clinician's.
Her online prescription may be compounded semaglutide. If it is, the clinician reviews her current dose and decides with her what to prescribe. GoodLife Health prescribes branded, FDA-approved medication only. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. A clinician's license carries the responsibility for what is prescribed.
Whatever is prescribed goes to the pharmacy Dana chooses, at that pharmacy's own price. In September 2026, Novo Nordisk listed Wegovy pens through NovoCare at $199 a month for the first two fills and $349 a month after. The $199 price is an introductory offer for new patients through December 2026. The Wegovy pill was listed from $149 a month at lower doses. GoodLife Health sets nothing, sees nothing and takes nothing on medication. Whether Dana's plan covers a medication is between her, the plan and the pharmacy.
Dana raised two objections before she joined. She already had a prescriber. She also knew the drug was the expensive part. Both are fair. The prescriber she has writes the refill. What she has never had is a clinician who measures before the dose changes. The medication bill goes to the pharmacy whether or not she joins. The membership pays for the measuring and for the person who reads the results with her.
Month 1: the baseline and the first visit
The panel covers nine biomarkers, drawn four times a year. At goal weight, the clinician reads first the markers her annual panel left out. Fasting Insulin and Hemoglobin A1c (HbA1c) are read together. Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP are in every panel, which gives a view of cardiovascular risk that a total cholesterol cannot. TSH With Reflex To Free T4 is drawn every quarter, because thyroid function belongs in any honest reading of weight and energy. The Comprehensive Metabolic Panel, the CBC and the Lipid Panel, Standard complete the picture.
Then comes the first video visit. The clinician walks Dana through each result and what it means for the decision ahead. She brings the forum stories, her travel weeks and her fear of starting over. All of it belongs in the visit.
Holding the dose, stepping it down and stopping are all on the table. The fee does not change with the answer. The membership costs $299 a month at every dose, with no molecule upcharge and no dose upcharge. Nothing in the arrangement leans toward more medication.
Whichever path they take is written down with a date to check it. For this composite, assume they agree to hold the dose for one quarter and revisit it on the second panel. Another patient with different numbers might step down at once.
Month 2: between visits
Most of what matters in month two happens in messages. Dana notices her hunger is louder on travel weeks and writes to the care team from a hotel room. The care team answers between visits. If a question needs a conversation, a video visit is part of the membership. None of it is billed separately.
The pharmacy bills the medication on its own terms. Any return or refund of medication follows that pharmacy's own policy. For the first time since she started treatment, the person reading Dana's messages has also read her panel.
Month 3: the second panel
About 90 days after the first draw, the same markers are drawn again. For the first time, someone can lay two of Dana's panels side by side on a known plan. If Fasting Insulin, Hemoglobin A1c (HbA1c) and the lipid markers hold, the next step down can be discussed with evidence behind it. If they move, the clinician and Dana talk about why before anything else changes.
Then the cycle repeats. Our guide to the direct primary care visit describes the quarterly review as a much more frequent replacement for the single annual look. The panel is how the plan stays honest between those reviews.
What the membership does not do
It does not promise that Dana keeps the weight off. It does not replace her insurance, which she keeps for catastrophic coverage. It does not promise that a medication will be covered or that a prior authorization will succeed. Prior authorization is the pharmacy's process. The membership is also narrower than full-scope primary care. Its scope is cardiometabolic health, meaning the markers above and the medication they inform.
What to do this week, whether or not you join
Most of what would help Dana this week does not require a membership. The same is true for you.
- Ask your doctor's office for the panel itself, with each number and the date it was drawn. The word fine is only a summary.
- Check which markers are on it. If Fasting Insulin, ApoB, Lipoprotein (A) and Hs-CRP are missing, the word fine never covered them.
- Write down your current dose, the date you reached goal and how your hunger has behaved on that dose.
- Send your prescriber one question in writing. What will be measured before my dose changes?
- Do not change the dose on your own until a clinician has answered that question.
If the answers come back complete and someone already follows your markers every quarter, you are in good hands. Stay there.
Who this is not for
This membership is the wrong fit for someone who wants the next refill without a blood draw. The $99-a-month compounded app exists for that purchase. We prescribe branded, FDA-approved medication only and draw labs before we change a dose.
It is also the wrong fit if you want a promise that the weight stays off. Nobody can honestly make that promise. We do not make it.
If you are looking for a plan to replace your insurance, keep looking. The membership pairs with insurance for catastrophic coverage. If you want one practice for every medical need, from a sprained ankle to a skin check, our scope is narrower than that. We care only for patients who live in the United States. If your doctor already draws ApoB, Fasting Insulin and Hemoglobin A1c (HbA1c) every quarter and talks your dose through with you, you may not need us at all.
For everyone else, the terms are plain. The membership is $299 a month. At sign-up, $598 is held on your card to cover the first two months and is charged only once a clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, the membership is month to month. The fee buys four lab panels a year with every result in your hands, a clinician who stays and messaging with the care team between video visits. Any medication goes to the pharmacy you choose at that pharmacy's own price. GoodLife Health takes nothing on it. In return, you get the diagnosis a rushed visit never produced, your markers followed every quarter and no more eight-minute visits. We test first and treat second. We sell neither the drug nor the dose. You are at goal weight now, which is when the dose decision gets made. The first panel belongs before it.
Related Reading
- Cardiometabolic Optimization: The Definitive Guide
- What a Direct Primary Care Visit Actually Looks Like (2026)
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss